朝阳区三间房地区定福庄西街社区卫生服务站等8家定点医药机构因不能继续为参保人员提供服务，被 中止医保服务协议。海淀区北安河社区卫生服务中心等3家定点医药机构因已注销等原因，被解除医保 服务协议。参保人员在上述11家医药机构发生的费用医保基金不予支付。 2月1日起，北京市新增6家定点医药机构，7家定点医药机构恢复医保服务。 市医保局介绍，新增的6家定点医药机构分别为：朝阳区东坝地区畅颐园社区卫生服务站、昌平区沙河 社区卫生服务中心丽春湖社区卫生服务站、房山区蒲洼乡东村村卫生室、房山区蒲洼乡宝水村卫生室、 房山区史家营乡柳林水村卫生室、门头沟区大峪街道龙坡社区卫生服务站。同时，朝阳区管庄地区远洋 一方社区卫生服务站等7家定点医药机构恢复医保服务。 （来源：千龙网） ...

Core Viewpoint - Han Commercial Group Co., Ltd. is expected to report a net loss for the year 2025, continuing its trend of negative profitability from the previous year [2][3]. Group 1: Performance Forecast - The company anticipates a net profit attributable to shareholders of the parent company in the range of -90 million to -60 million yuan for the year 2025 [2][3]. - The expected net profit, excluding non-recurring gains and losses, is projected to be between -49.98 million and -19.98 million yuan [4]. Group 2: Previous Year’s Performance - In the previous year, the total profit was -5.4686 million yuan, with a net profit attributable to shareholders of the parent company at -14.5872 million yuan [6]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -38.0898 million yuan [6]. Group 3: Reasons for Expected Loss - The primary reason for the anticipated loss in 2025 is the planned impairment of goodwill related to the Wuhan Huake Reproductive Obstetrics Hospital asset group, estimated to be between 80 million and 90 million yuan [8]. - This non-cash impairment is expected to significantly impact the company's net profit for the year [8].

Core Viewpoint - The company, Han Commercial Group Co., Ltd., anticipates a continued loss for the fiscal year 2025, projecting a net profit attributable to shareholders of between -90 million and -60 million yuan, indicating a worsening financial situation compared to the previous year [2][3]. Group 1: Performance Forecast - The performance forecast period is from January 1, 2025, to December 31, 2025 [3]. - The company expects a net profit attributable to shareholders of between -90 million and -60 million yuan for 2025, continuing the trend of losses from the previous year [2][3]. - The projected net profit, excluding non-recurring gains and losses, is estimated to be between -49.98 million and -19.98 million yuan [4]. Group 2: Previous Year’s Financial Performance - In the previous year, the total profit was -5.4686 million yuan, with a net profit attributable to shareholders of -14.5872 million yuan [6]. - The net profit attributable to shareholders, excluding non-recurring gains and losses, was -38.0898 million yuan [6]. - The earnings per share for the previous year were -0.0494 yuan [7]. Group 3: Reasons for Expected Loss - The company adheres to the "Enterprise Accounting Standards" and related accounting policies, conducting year-end impairment tests on relevant assets [8]. - A significant factor contributing to the expected loss for 2025 is the planned goodwill impairment related to the Wuhan Huake Reproductive Obstetrics Hospital asset group, estimated between 80 million and 90 million yuan [8]. - The final amount of goodwill impairment will be determined by the evaluation and audit conducted by the company's appointed assessment and audit institutions [8].

Core Viewpoint - Haocen Medical is expected to report a net profit loss of 65 million to 130 million yuan for the entire year of 2025 due to increased market competition and rising customer acquisition costs in the dental medical service sector [1][2]. Financial Performance Summary - For the first three quarters of 2025, the company's main revenue was 527 million yuan, a year-on-year decrease of 17.03% [2]. - The net profit attributable to shareholders was -26.41 million yuan, a year-on-year decline of 295.68% [2]. - The net profit after deducting non-recurring gains and losses was -24.52 million yuan, down 288.77% year-on-year [2]. - In Q3 2025, the company's single-quarter main revenue was 213 million yuan, a decrease of 15.72% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -2.66 million yuan, a decline of 120.54% year-on-year [2]. - The single-quarter net profit after deducting non-recurring gains and losses was -0.97 million yuan, down 107.53% year-on-year [2]. - The company's debt ratio stood at 71.72%, with investment income of 2.67 million yuan and financial expenses of 31.15 million yuan [2]. - The gross profit margin was 47.72% [2]. Reasons for Performance Change - The decline in performance is attributed to intensified market competition, increased customer acquisition costs, and a significant drop in average customer spending in the dental medical service sector [2]. - The company plans to recognize goodwill impairment and long-term equity investment impairment based on cautious principles due to the expected recoverable amounts being lower than their book values [2].

SDICSI 2026 年 1 月 29 日 卓正医疗 (2677.HK) 卓正医疗 IPO 点评 公司概览 行业状况及前景 根据弗若斯特沙利文的数据，中国私立中高端医疗服务市场的总收入由 2020 年 的 1,930 亿元增长到 2024 年的 4,263 亿元，复合年增长率为 21.9%，预计 2024 年至 2029 年将以 14.3%的复合年增长率增长，到 2029 年达到 8,314 亿元。 优势与机遇 1）以 2024 年收入计为中国第三大私立中高端综合医疗服务机构，品牌知名度 高；2）家庭医疗模式，将实体及线上医疗服务融为一体；3）专业、稳定的医生 团队，结构化的人才发展框架；4）集中化、标准化及数字化的管理系统，以及 提前采用人工智能技术，确保服务质量、运营效率和可扩张性；5）稳定的高级 管理团队，拥有丰富多样的行业经验。 弱项与风险 行业竞争加剧、医保控费等政策风险、医疗事故等突发事件风险等。 招股信息 招股时间为 2026 年 1 月 29 日至 2 月 3 日，上市时间为 2 月 6 日。 基石投资者 卓正医疗是中国知名的私立医疗服务机构，核心聚焦中高端医疗服务市场。截至 2026 年 ...

Core Viewpoint - The company, 弘毅文化集团, has agreed to sell its entire stake in Heartily Health Limited for a total consideration of 1 Hong Kong dollar, which will result in the removal of the subsidiary from the group's consolidated financial statements [1][2] Group 1 - The sale agreement was made between Meerkat Health Holdings Limited, a wholly-owned subsidiary of the company, and Mr. Xu Chun Sheng, the buyer [1] - Heartily Health Limited, the target company, is primarily engaged in investment holding and operates in the pharmaceutical e-commerce and smart healthcare services sectors [1] - Following the completion of the sale on January 30, 2026, the financial performance, assets, and liabilities of the target company will no longer be included in the group's consolidated financial statements [1] Group 2 - The divestment allows the company to optimize its asset allocation and focus on areas with stronger growth potential [2] - By eliminating loss-making operations, the company can reallocate internal resources to support its core businesses in entertainment, media, and digital healthcare services [2] - This strategic move is expected to enhance the overall financial flexibility of the group [2]

Core Viewpoint - Haijia Medical announced that it expects to achieve a quarter-on-quarter increase in revenue and patient visits in the second half of 2025, indicating a marginal improvement in operational performance [1] Financial Performance - The company's operating cash flow for the year is projected to be between RMB 940 million and RMB 1 billion, representing a year-on-year growth of approximately 33% to 41% [1] - The net bank debt is expected to decrease by RMB 340 million by the end of 2025, with capital expenditures anticipated to decline by 16% to 24% year-on-year [1] Operational Quality - The company is solidifying its operational quality, with ongoing construction projects nearing completion, which may further reduce future capital expenditure [1] - The apparent net profit has decreased primarily due to goodwill impairment, which is a one-time accounting adjustment and does not involve actual cash outflow [1]

Core Viewpoint - Haijia Medical announced that it expects to achieve a quarter-on-quarter increase in revenue and patient visits in the second half of 2025, indicating marginal improvement in operations [1] Financial Performance - The company's operating cash flow for the year is projected to be between RMB 940 million and RMB 1 billion, representing a year-on-year growth of approximately 33% to 41% [1] - The net bank debt is expected to decrease by RMB 340 million by the end of 2025, while capital expenditures are anticipated to decline by 16% to 24% year-on-year [1] Operational Quality - The company is solidifying its operational quality, with ongoing construction projects nearing completion, which is likely to further reduce future capital expenditure [1] - The apparent net profit has decreased primarily due to goodwill impairment, which is a one-time accounting adjustment and does not involve actual cash outflow [1]

【大河财立方 记者 席韶阳 通讯员 唐爱红】新华保险在医康养生态领域再添重磅战略合作对象。近日，新华保险与New Frontier Group Limited（以下简称新 风天域集团）在北京举行战略合作签约仪式。双方将合作升级"保险+医疗健康"融合模式，为客户提供覆盖全生命周期的医疗健康解决方案。 新风天域集团表示，本次与新华保险达成战略合作，双方将共同努力开创"保险+医疗健康"融合新篇章，未来将依托其多元化的业务矩阵，为"保险+医疗"融 合模式提供支持。未来合作中，双方将充分发挥各自优势，共同探索并推动"服务给付型健康保险"产品的创新与发展，为新华保险的客户提供更安全、专业 和便捷的医疗健康服务。 新华保险长期锚定"中国一流的以保险业务为核心的金融服务集团"发展愿景，深化"保险+服务+投资"三端协同。新华保险相关负责人表示，未来，将以此次 战略合作为新起点，继续携手新风天域集团等生态伙伴，持续深化"保险+医疗健康"模式，扎实推进资源整合、提升服务协同能力，持续拓展医疗服务网 络，优化健康管理服务闭环，扎实构建"卓越医疗"服务体系，为"健康中国"建设注入新动能。 据悉，为积极响应"健康中国"战略，推动保险保障 ...

Core Viewpoint - The "Climbing the Peak and Crossing the Ridge" project in Jinan aims to enhance clinical specialty construction in public hospitals, with a focus on improving regional medical service capabilities and levels through the selection of key specialties [7]. Group 1: Selected Specialties - The Jiyang District People's Hospital has two specialties, Pediatrics and Orthopedics, included in the "Climbing the Peak" initiative, while seven other specialties, including Emergency Medicine and Critical Care, are part of the "Crossing the Ridge" plan [7]. - A total of 110 key specialties were selected across three categories: "Climbing the Peak," "Climbing the Mountain," and "Crossing the Ridge," supported by various levels of government funding [7]. Group 2: Pediatric Specialty - The Pediatric department at Jiyang District People's Hospital is recognized as a key clinical specialty at both the provincial and municipal levels, offering comprehensive services including neonatal care and pediatric emergency services [8][9]. - The department has established a full-service system for critical care and has successfully treated numerous cases of severe pneumonia and premature infants [9]. Group 3: Orthopedic Specialty - The Orthopedic department focuses on joint, spine, and limb microsurgery, recognized as a key clinical specialty in Jinan since 2022, and is equipped to perform advanced procedures such as joint replacements and minimally invasive spine treatments [10]. - The department aims to provide personalized treatment plans for common and complex orthopedic conditions, enhancing patient recovery times [10]. Group 4: Other Specialties in the "Crossing the Ridge" Plan - The Emergency Medicine and Critical Care departments work together to provide a closed-loop system for critical care, equipped with advanced emergency equipment and trained personnel [11]. - The Cardiovascular department specializes in coronary heart disease and hypertension, being the only center in the region capable of performing emergency PCI treatments [12]. - The Geriatric and Rehabilitation departments focus on chronic disease management and rehabilitation services tailored to the aging population, achieving recognition in various skill competitions [12]. - The Oncology department is recognized as a cancer center and leads in advanced treatment techniques, while the Infectious Diseases department has established a specialized clinic for tuberculosis screening and prevention [13]. Group 5: Future Directions - The Jiyang District People's Hospital aims to leverage its recent recognitions to enhance patient-centered care and specialty development, focusing on improving diagnostic and treatment capabilities for complex cases [13].